The past decade has seen important advances in the clinical utility of
serotonergic agents. The putative novel anxiolytic effects of 5-HT1A
partial agonists such as buspirone, the antidepressant effects of selective
serotonin (5-HT) uptake blockers such as fluoxetine, and the unique and
potent antiemetic effects of 5-HT3 antagonists in cancer chemotherapy are
excellent examples of the clinical relevance of selective 5-HT receptor
agents. The increasing ability to modulate serotonergic neurotransmission
through distinct 5-HT receptor subtypes should greatly facilitate the
analysis of 5-HT in both normal and abnormal human brain function.Abstract Teaser